ClinicalTrials.gg
RecruitingNCT07339631Updated Mar 20, 2026

Sodium Aescinate for the Treatment of Low Back Pain (LBP) in Adults

A Phase 1 interventional study of Sodium Aescinate Tablets and Placebo in Low Back Pain, Paraspinal Muscle and CLBP - Chronic Low Back Pain, sponsored by Xijing Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by Xijing Hospital · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Low Back Pain with a site in China — 17 open to participants now, 19 under way, none of them phase 3. Low Back Pain · China.

Planned enrollment
33rd of 42
40 · median 84
Started
2026
with 7 others
Phase 1
2 of 49
1 open now
Primary completion
2029-09
later than 18 of 18 live
Registered
40th of 49
by date
Lead sponsor
2 of 49
Xijing Hospital

Among the 49 studies in Low Back Pain with a site in China, this one is the 33rd largest by planned enrollment of the 42 interventional ones that give a count, is one of 8 that started in 2026, is one of 2 in phase 1, reaches primary completion later than 18 of the 18 other live ones, and was the 40th registered.

Low Back Pain

2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

17 of the 49 studies in Low Back Pain with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Low Back Pain with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to assess the clinical efficacy and safety of sodium aescinate in treating low back pain (LBP) in adult participants.

Read the detailed description

The goal of this clinical trial is to evaluate the efficacy and safety of oral sodium aescinate in improving symptoms and function in adult participants aged 18-65 years with low back pain (LBP) lasting at least 12 weeks and a Visual Analog Scale (VAS) score > 4 points. The main questions it aims to answer are:

  1. Does oral sodium aescinate tablets reduce pain intensity (measured by VAS score) in adult LBP patients at 1, 3, and 6 weeks after treatment?
  2. Is oral sodium aescinate tablets safe for adult LBP patients, with an acceptable adverse event profile during the 6-week treatment period?

Researchers will compare participants receiving sodium aescinate (experimental group) to those receiving a placebo (control group) to see if the experimental intervention results in significant improvements in pain, disability, functional status, and lumbar paraspinal muscle conditions (cross-sectional area and fat infiltration rate) compared to the placebo.

Participants will:

  1. Undergo screening (medical history review, physical examination, and relevant tests) to confirm eligibility and sign an informed consent form.
  2. Be randomly assigned to either the experimental or control group in a 1:1 ratio.
  3. Take 2 tablets of the assigned study medication (sodium aescinate tablets or placebo) twice daily for 6 consecutive weeks.
  4. Complete follow-up visits at baseline (week 0), week 1, week 3, and week 6 for efficacy assessments (VAS, Oswestry Disability Index [ODI], Japanese Orthopaedic Association [JOA] score, 36-Item Short Form Health Survey [SF-36] score).
  5. Undergo lumbar MRI scans at baseline and week 6 to measure paraspinal muscle cross-sectional area and fat infiltration rate.
  6. Report any adverse events experienced during the 6-week treatment period.
03

Conditions studied

  • Low Back Pain
  • Paraspinal Muscle
  • CLBP - Chronic Low Back Pain
  • Non-specific Chronic Low Back Pain

Browse trials for

Keywords

  • low back pain
  • sodium aescinate tablets
  • double-blind randomized controlled trial
  • CLBP - Chronic Low Back Pain
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Meets the diagnostic criteria for chronic low back pain (cLBP) recommended by the Clinical Practice Guidelines for Chronic Low Back Pain in China (2024 Edition): the course of disease lasts at least 12 weeks, with pain occurring in the region below the lower costal margin, above the gluteal crease (horizontal gluteal fold), and between the midaxillary lines on both sides, which may be accompanied by pain in one or both lower extremities.
  2. Has moderate to severe pain, with a Visual Analog Scale (VAS) score > 4 points.
  3. Aged between 18 and 65 years old.
  4. Has a clear understanding of the study content, good compliance, and high willingness to cooperate.
  5. Has signed a written form voluntarily.

Exclusion criteria

Exclusion Criteria:

  1. Is in the acute pain phase or acute exacerbation of chronic pain.
  2. Has low back pain caused by other reasons such as infectious diseases or tumors, including but not limited to spinal tumors, spinal tuberculosis, spinal cord infections, etc.
  3. Has a history of allergy to sodium aescinate.
  4. Suffers from systemic diseases or organ dysfunction.
  5. Has participated in other clinical trials within 1 month before enrollment.
  6. Has severe mental illness or other conditions that prevent cooperation with the study.
  7. Is a pregnant or lactating woman, or a woman planning to become pregnant.
  8. Has metal implants or other conditions that are not suitable for MRI examination.
  9. Is considered by the researcher to have conditions that are unfavorable for completing the study course.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Participants in this arm will receive oral sodium aescinate mimetic tablets (placebo), which are identical to the experimental drug (sodium aescinate tablets) in appearance, dosage form, color, and taste.

    Drug: Placebo

  • Experimental
    Sodium Aescinate Tablets

    Participants in this arm will receive oral sodium aescinate tablets.

    Drug: Sodium Aescinate Tablets

Interventions

  • DrugSodium aescinateStudies of Sodium aescinateSodium aescinate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    This intervention is an oral sodium aescinate tablets. Each tablet contains 30mg of sodium aescinate as the active ingredient. Eligible participants will take 2 tablets per dose, twice daily (bid), for a continuous 6-week treatment period. The drug is provided by Shandong Luye Pharmaceutical Co., Ltd. and is administered in a double-blind manner, with the placebo control having identical appearance, dosage form, and administration route to ensure masking. The intervention aims to improve pain, disability, and functional status in adult patients with chronic low back pain by exerting anti-inflammatory, detumescent, and microcirculation-improving effects.

  • DrugPlacebo

    The intervention dosage is 2 tablets (30mg/tablet) per administration, twice daily (bid), for a continuous 6-week treatment period. During the study, participants will complete follow-up visits at baseline (week 0), week 1, week 3, and week 6 for efficacy assessments (VAS, ODI, JOA, SF-36 scores) and undergo lumbar MRI scans at baseline and week 6 to measure paraspinal muscle cross-sectional area and fat infiltration rate. All adverse events experienced during the treatment period will be recorded in detail.

06

What researchers measure

Primary outcomes

  1. Pain Intensity Assessed by Visual Analog Scale (VAS) Score

    Pain intensity will be assessed using the Visual Analog Scale (VAS), a validated tool with a score range from 0 to 10 points. A score of 0 represents no pain, and a score of 10 represents the most severe pain imaginable. This outcome measure evaluates changes in pain intensity in adults with chronic low back pain (cLBP) following treatment with oral sodium aescinate tablets.

    Time frame: Baseline (Day 0, pre-intervention), Week 1, Week 3, and Week 6 after the start of treatment

Secondary outcomes

  1. Disability Severity Assessed by Oswestry Disability Index (ODI) Score

    Disability related to low back pain will be assessed using the Oswestry Disability Index (ODI), a widely used questionnaire with a total score range of 0 to 50 points. Higher scores indicate greater disability in activities of daily living. This outcome measure evaluates changes in functional disability in cLBP patients after treatment.

    Time frame: Baseline (Day 0, pre-intervention), Week 1, Week 3, and Week 6 after the start of treatment

  2. Lumbar Functional Status Assessed by Japanese Orthopaedic Association (JOA) Score

    Lumbar spine function will be evaluated using the Japanese Orthopaedic Association (JOA) score, which ranges from 0 to 29 points. Lower scores indicate more severe functional impairment. This outcome measure assesses changes in lumbar spine function following treatment.

    Time frame: Baseline (Day 0, pre-intervention), Week 1, Week 3, and Week 6 after the start of treatment

  3. Health-Related Quality of Life Assessed by SF-36 Total Score

    Health-related quality of life will be assessed using the 36-Item Short Form Health Survey (SF-36). The total score ranges from 0 to 100 points, with higher scores indicating better overall health status. This outcome measure evaluates changes in overall quality of life in cLBP patients following treatment.

    Time frame: Baseline (Day 0, pre-intervention), Week 1, Week 3, and Week 6 after the start of treatment

  4. Lumbar Paraspinal Muscle Cross-Sectional Area Assessed by MRI

    Lumbar MRI will be used to measure the cross-sectional area of paraspinal muscles as an objective indicator of muscle mass. This outcome measure evaluates changes in paraspinal muscle size following treatment with sodium aescinate tablets.

    Time frame: Baseline (Day 0, pre-intervention) and Week 6 after the start of treatment

  5. Lumbar Paraspinal Muscle Fat Infiltration Rate Assessed by MRI

    Lumbar MRI will be used to assess the fat infiltration rate of paraspinal muscles as an indicator of muscle quality. This outcome measure evaluates changes in paraspinal muscle composition following treatment.

    Time frame: Baseline (Day 0, pre-intervention) and Week 6 after the start of treatment

Other outcomes

  1. Incidence of Adverse Events During Treatment

    All adverse events (AEs) occurring during the 6-week treatment period will be recorded. For each AE, the type, severity, duration, and relationship to the study drug will be documented to evaluate the safety of oral sodium aescinate tablets.

    Time frame: Within 6 weeks after the start of treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Sep 2029, 42 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2025
First posted
Jan 14, 2026
StartActual
Mar 1, 2026
Primary completionEst.
Sep 1, 2029
CompletionEst.
Sep 1, 2029
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07339631
Lead sponsor
Xijing Hospital
Responsible party
Bo Gao, MD (principal investigator, Xijing Hospital) — Principal investigator
First posted
Jan 14, 2026
Start date
Mar 1, 2026
Primary completion
Sep 1, 2029 (estimated)
Completion
Sep 1, 2029 (estimated)
Last update
Mar 20, 2026

Study contacts

Bo Gao, MD, PhD
Contact
gaobofmmu@hotmail.com
029-84775507

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium aescinate

Start the discussion